Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease

Arthritis and Rheumatism

Volumn 63, Issue 5, 2011, Pages 1416-1425

  Bogatkevich, Galina S ^a   Ludwicka Bradley, Anna ^a   Nietert, Paul J ^a   Akter, Tanjina ^a   Van Ryn, Joanne ^b   Silver, Richard M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DABIGATRAN ETEXILATE; SMAD3 PROTEIN; THROMBIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; INFLAMMATORY CELL; INTERSTITIAL LUNG DISEASE; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADMINISTRATION, ORAL; ANIMALS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLEOMYCIN; DISEASE MODELS, ANIMAL; FEMALE; LUNG DISEASES, INTERSTITIAL; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS; THROMBIN;

EID: 79955558187     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30255     Document Type: Article

References (44)

1. Chambers RC,. Procoagulant signaling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 2008; 153 Suppl 1: S367-78. (Pubitemid 351340998)
2. Howell DC, Laurent GJ, Chambers RC,. Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis. Biochem Soc Trans 2002; 30: 211-6.
3. Green D,. Coagulation cascade. Hemodial Int 2006; 10 Suppl 2: S2-4. (Pubitemid 44489904)
4. Mann KG,. Thrombin formation. Chest 2003; 124: 4-10S.
5. Ludwicka-Bradley A, Bogatkevich G, Silver RM,. Thrombin- mediated cellular dysfunction in pulmonary fibrosis associated with systemic sclerosis (scleroderma). Clin Exp Rheumatol 2004; 22 Suppl 33: S38-46. (Pubitemid 39162034)
6. Coughlin SR,. Thrombin signaling and protease-activated receptors. Nature 2000; 407: 258-64.
7. Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A,. Thrombin differentiates normal lung fibroblast to a myofibroblast phenotype via proteolytically activated receptor-1 and protein kinase C-dependent pathway. J Biol Chem 2001; 276: 45184-92.
8. Bogatkevich GS, Gustilo E, Oates J, Feghali-Bostwick C, Harley RA, Silver RM, et al. Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2005; 288: L190-201. (Pubitemid 40023901)
9. Ohba T, McDonald JK, Silver RM, Strange C, LeRoy EC, Ludwicka A,. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of the platelet-derived growth factor α-receptor. Am J Respir Cell Mol Biol 1994; 10: 405-12.
10. Gray AJ, Bishop JE, Reeves JT, Laurent GJ,. Aα and Bβ chains of fibrinogen stimulate proliferation of human fibroblasts. J Cell Sci 1993; 104: 409-13. (Pubitemid 23098679)
11. Bachhuber BG, Sarembock IJ, Gimple LW, Owens GK,. α-thrombin induces transforming growth factor-β1 mRNA and protein in cultured vascular smooth muscle cells via a proteolytically activated receptor. J Vasc Res 1997; 34: 41-8. (Pubitemid 27105913)
12. Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE, Laurent GJ,. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem 2000; 275: 35584-91.
13. Bogatkevich GS, Ludwicka-Bradley A, Paul J,. Nietert, Silver RM. Scleroderma lung fibroblasts: contractility and connective tissue growth factor. In, Gabbiani G, Chaponnier C, Desmouliere A, editors. Myofibroblasts. Georgetown (TX): Landes Bioscience; 2006. p 25-31.
14. 1-induced proinflammatory and profibrotic mediator release following lung injury. Ann N Y Acad Sci 2007; 1096: 86-8. (Pubitemid 47092501)
15. Ludwicka-Bradley A, Tourkina E, Suzuki S, Tyson E, Bonner M, Fenton JW II, et al. Thrombin upregulates interleukin-8 in lung fibroblasts via cleavage of proteolytically activated receptor-I and protein kinase C-γ activation. Am J Respir Cell Mol Biol 2000; 22: 235-43. (Pubitemid 30351487)
16. Tourkina E, Hoffman S, Fenton JW II, Lipsitz S, Silver RM, Ludwicka-Bradley A,. Depletion of protein kinase CÏμ in normal and scleroderma lung fibroblasts has opposite effects on tenascin expression. Arthritis Rheum 2001; 44: 1370-81. (Pubitemid 32537536)
17. Chambers RC, Dabbagh K, McAnulty RJ, Gray AJ, Blanc-Brude OP, Laurent GJ,. Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem J 1998; 333: 121-7. (Pubitemid 28342501)
18. Armstrong MT, Fenton JW II, Andersen TT, Armstrong PB,. Thrombin stimulation of matrix fibronectin. J Cell Physiol 1996; 166: 112-20. (Pubitemid 26017785)
19. Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001; 159: 1383-95. (Pubitemid 32947968)
20. Howell DC, Johns RH, Lasky JA, Shan B, Scotton CJ, Laurent GJ, et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005; 166: 1353-65. (Pubitemid 40586507)
21. Sorbera LA, Bozzo J, Castaner J,. Dabigatran/dabigatran etexilate. Drugs Future 2005; 30: 877-85.
22. Bogatkevich GS, Ludwicka-Bradley A, Silver RM,. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum 2009; 60: 3455-64.
23. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R,. Proteinase-activated receptors. Pharmacol Rev 2001; 53: 245-82. (Pubitemid 32476117)
24. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N,. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98: 155-62. (Pubitemid 47078782)
25. Silver RM, Metcalf JF, Stanley JH, LeRoy EC,. Interstitial lung disease in scleroderma: analysis by bronchoalveolar lavage. Arthritis Rheum 1984; 27: 1254-62. (Pubitemid 15212138)
26. Ashcroft T, Simpson JM, Timbrell V,. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467-70. (Pubitemid 18098428)
27. Laurent GJ, Cockerill P, McAnulty RJ, Hasting JR,. A simplified method for quantitation of the relative amounts of type I and type III collagen in small tissue samples. Anal Biochem 1981; 113: 301-12. (Pubitemid 11012540)
28. Troconiz IF, Tillmann C, Liesenfeld KH, Schaefer HG, Stangier J,. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective hip replacement surgery. J Clin Pharmacol 2007; 47: 371-82. (Pubitemid 46294714)
29. Palm M, Frankenberg L, Johansson M, Jalkesten E,. Evaluation of coagulation tests in mouse plasma. Comp Haematol Int 1997; 7: 243-6. (Pubitemid 28014319)
30. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M,. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008; 40: 362-82. (Pubitemid 351249887)
31. Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, et al. Elevated levels of platelet derived growth factor and transforming growth factor-β1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995; 10: 1876-83.
32. Wilson MS, Wynn TA,. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009; 2: 103-21.
33. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004; 138: 540-6. (Pubitemid 39573637)
34. Bonner JC,. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15: 255-73. (Pubitemid 38781050)
35. Maeda A, Ishioka S, Taooka Y, Hiyama K, Yamakido M,. Expression of transforming growth factor-β1 and tumour necrosis factor-α in bronchoalveolar lavage cells in murine pulmonary fibrosis after intraperitoneal administration of bleomycin. Respirology 1999; 4: 359-63. (Pubitemid 30016284)
36. Tani K, Ogushi F, Takahashi H, Kawano T, Endo T, Sone S,. Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats-significance in bleomycin-induced pulmonary fibrosis. J Med Invest 1997; 44: 59-65. (Pubitemid 127495234)
37. Hernandez-Rodriguez NA, Cambrey AD, Harrison NK, Chambers RC, Gray AJ, Southcott AM, et al. Role of thrombin in pulmonary fibrosis. Lancet 1995; 346: 1071-3.
38. Thuillier R, Favreau F, Celhay O, Macchi L, Milin S, Hauet T,. Thrombin inhibition during kidney ischemia-reperfusion reduces chronic graft inflammation and tubular atrophy. Transplantation 2010; 90: 612-21.
39. Favreau F, Thuillier R, Cau J, Milin S, Manguy E, Mauco G, et al. Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model. Am J Transplant 2010; 10: 30-9.
40. Moore BB, Hogaboam CM,. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L152-60. (Pubitemid 351253350)
41. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-27.
42. Kim R, Meyer KC,. Therapies for interstitial lung disease: past, present and future. Ther Adv Respir Dis 2008; 2: 319-38.
43. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-82. (Pubitemid 41324435)
44. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J,. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30: 1885-9.